Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone

Journal Article · Wed Mar 01 00:00:00 EST 1989 · Radiographics; (United States)

DOI:https://doi.org/10.1148/radiographics.9.2.2467331· OSTI ID:6150273

Robinson, R G; Blake, G M; Preston, D F; McEwan, A J; Spicer, J A; Martin, N L; Wegst, A V; Ackery, D M

Two hundred and two patients with bone pain from metastatic cancer were treated with 40 microCi/kg of Sr-89. Patients were followed with pain diaries, records of medication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup survived at least 3 months, including 100 with prostate and 28 with breast carcinoma. Eighty of the 100 patients with prostate cancer responded, and 25 of the 28 breast cancer patients improved. Ten patients with prostate cancer and five with breast cancer became pain free. Little hematologic depression was noted. Sr-89 kinetic studies showed that strontium taken up in osteoblastic areas remained for 100 days. The tumor-to-marrow absorbed dose ratio was 10:1.

• Research Organization: Univ. of Kansas Medical Center, Kansas City (USA)
• OSTI ID: 6150273
• Journal Information: Radiographics; (United States), Vol. 9:2
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MAMMARY GLANDS
CARCINOMAS
METASTASES
RADIOTHERAPY
PROSTATE
SKELETON
RADIATION DOSES
PAIN
PATIENTS
STRONTIUM 89
SURVIVAL CURVES
ALKALINE EARTH ISOTOPES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
EVEN-ODD NUCLEI
GLANDS
INTERMEDIATE MASS NUCLEI
ISOTOPES
MALE GENITALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
RADIOISOTOPES
RADIOLOGY
STRONTIUM ISOTOPES
SYMPTOMS
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)